Genzyme Bids For AnorMED Eyeing Stem Cell Transplantation Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme appeals directly to shareholders after rejection from AnorMed’s board of directors.
You may also be interested in...
Genzyme Wins AnorMED As Millennium Backs Out Of Bidding War
Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.
Genzyme Wins AnorMED As Millennium Backs Out Of Bidding War
Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.
Genzyme Raises Bid For AnorMED, Emphasizing Market Advantage For Mozobil
Latest bid is 12.5% higher than Millennium’s, but the firm will have three days to match it if needed.